Reaction Details |
| Report a problem with these data |
Target | Adenosine receptor A2a |
---|
Ligand | BDBM26249 |
---|
Substrate/Competitor | BDBM21190 |
---|
Meas. Tech. | Receptor Binding Assay |
---|
pH | 7.4±n/a |
---|
Temperature | 295.15±n/a K |
---|
Ki | 0.61±0.07 nM |
---|
Citation | Zhang, X; Tellew, JE; Luo, Z; Moorjani, M; Lin, E; Lanier, MC; Chen, Y; Williams, JP; Saunders, J; Lechner, SM; Markison, S; Joswig, T; Petroski, R; Piercey, J; Kargo, W; Malany, S; Santos, M; Gross, RS; Wen, J; Jalali, K; O'Brien, Z; Stotz, CE; Crespo, MI; Diaz, JL; Slee, DH Lead Optimization of 4-Acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A Adenosine Receptor Antagonists for the Treatment of Parkinson's Disease. J Med Chem51:7099-7110 (2008) [PubMed] Article |
---|
More Info.: | Get all data from this article, Solution Info, Assay Method |
---|
|
Adenosine receptor A2a |
---|
Name: | Adenosine receptor A2a |
Synonyms: | A2A adenosine receptor (hA2A) | AA2AR_HUMAN | ADENOSINE A2 | ADENOSINE A2a | ADORA2 | ADORA2A | Adenosine A2A receptor (A2AAR) |
Type: | G Protein-Coupled Receptor (GPCR) |
Mol. Mass.: | 44716.46 |
Organism: | Homo sapiens (Human) |
Description: | P29274 |
Residue: | 412 |
Sequence: | MPIMGSSVYITVELAIAVLAILGNVLVCWAVWLNSNLQNVTNYFVVSLAAADIAVGVLAI
PFAITISTGFCAACHGCLFIACFVLVLTQSSIFSLLAIAIDRYIAIRIPLRYNGLVTGTR
AKGIIAICWVLSFAIGLTPMLGWNNCGQPKEGKNHSQGCGEGQVACLFEDVVPMNYMVYF
NFFACVLVPLLLMLGVYLRIFLAARRQLKQMESQPLPGERARSTLQKEVHAAKSLAIIVG
LFALCWLPLHIINCFTFFCPDCSHAPLWLMYLAIVLSHTNSVVNPFIYAYRIREFRQTFR
KIIRSHVLRQQEPFKAAGTSARVLAAHGSDGEQVSLRLNGHPPGVWANGSAPHPERRPNG
YALGLVSGGSAQESQGNTGLPDVELLSHELKGVCPEPPGLDDPLAQDGAGVS
|
|
|
BDBM26249 |
---|
BDBM21190 |
---|
Name | BDBM26249 |
Synonyms: | N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[6-(dimethylamino)pyridin-2-yl]pyrimidin-4-yl]acetamide | pyrazolylpyrimidine derivative, 16c |
Type | Small organic molecule |
Emp. Form. | C18H21N7O |
Mol. Mass. | 351.4056 |
SMILES | CN(C)c1cccc(n1)-c1cc(NC(C)=O)nc(n1)-n1nc(C)cc1C |
Structure |
|